Skip to main content

Cefprozil (Monograph)

Brand name: Cefzil
Drug class: Second Generation Cephalosporins
Chemical name: (6R, 7R)-7-[(R)-2-amino-2-(p-hydroxyphenyl)acetamido]-8-oxo-3-propenyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monohydrate
CAS number: 92665-29-7

Medically reviewed by Drugs.com on Sep 29, 2023. Written by ASHP.

Introduction

Antibacterial; β-lactam antibiotic; second generation cephalosporin.a

Uses for Cefprozil

Acute Otitis Media (AOM)

Treatment of AOM caused by Streptococcus pneumoniae, Haemophilus influenzae (including β-lactamase-producing strains), or Moraxella catarrhalis (including β-lactamase-producing strains).3 4 12 21 30 36 37 43 44 45 62 80 81

When anti-infectives indicated, AAP recommends high-dose amoxicillin or amoxicillin and clavulanate as drugs of choice for initial treatment of AOM; certain cephalosporins (cefdinir, cefpodoxime, cefuroxime, ceftriaxone) recommended as alternatives for initial treatment in penicillin-allergic patients without a history of severe and/or recent penicillin-allergic reactions.37

Pharyngitis and Tonsillitis

Treatment of pharyngitis and tonsillitis caused by S. pyogenes (group A β-hemolytic streptococci).80 81 Generally effective in eradicating S. pyogenes from nasopharynx; efficacy in prevention of subsequent rheumatic fever not established to date.80 81

AAP, IDSA, AHA, and others recommend a penicillin regimen (10 days of oral penicillin V or oral amoxicillin or single dose of IM penicillin G benzathine) as treatment of choice for S. pyogenes pharyngitis and tonsillitis;49 100 116 117 other anti-infectives (oral cephalosporins, oral macrolides, oral clindamycin) recommended as alternatives in penicillin-allergic patients.49 100 116 117

If an oral cephalosporin used, 10-day regimen of first generation cephalosporin (cefadroxil, cephalexin) preferred instead of other cephalosporins with broader spectrums of activity (e.g., cefaclor, cefdinir, cefixime, cefpodoxime, cefuroxime).100 116 117

Respiratory Tract Infections

Treatment of acute sinusitis caused by S. pneumoniae, H. influenzae (including β-lactamase-producing strains), or M. catarrhalis (including β-lactamase-producing strains).34 65 80 81 Because of variable activity against S. pneumoniae and H. influenzae, IDSA no longer recommends second or third generation oral cephalosporins for empiric monotherapy of acute bacterial sinusitis.143 Oral amoxicillin or amoxicillin and clavulanate usually recommended for empiric treatment.143 144 If an oral cephalosporin used as an alternative in children (e.g., in penicillin-allergic individuals), combination regimen that includes a third generation cephalosporin (cefixime or cefpodoxime) and clindamycin (or linezolid) recommended.143 144

Treatment of secondary bacterial infections of acute bronchitis caused by susceptible S. pneumoniae, H. influenzae (including β-lactamase-producing strains), or M. catarrhalis (including β-lactamase-producing strains).16 38 80 81

Treatment of acute bacterial exacerbation of chronic bronchitis caused by susceptible S. pneumoniae, H. influenzae (including β-lactamase producing strains), or M. catarrhalis (including β-lactamase producing strains).16 38 80 81

Treatment of mild to moderate community-acquired pneumonia† [off-label] (CAP).20 If an oral cephalosporin used as an alternative to penicillin G or amoxicillin for treatment of CAP caused by penicillin-susceptible S. pneumoniae, ATS and IDSA recommend cefdinir, cefditoren, cefpodoxime, cefprozil, or cefuroxime.20

Skin and Skin Structure Infections

Treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or S. pyogenes.10 35 63 80 81

Also has been used for treatment of uncomplicated skin and skin structure infections caused by S. epidermidis† [off-label], S. saprophyticus† [off-label], group B or G streptococci† [off-label], E. coli† [off-label], or K. pneumoniae†.10 35

Cefprozil Dosage and Administration

Administration

Oral Administration

Administer orally without regard to meals.80 81

Reconstitution

Reconstitute oral suspension at time of dispensing by adding the amount of water specified on the container in 2 equal portions; shake after each addition.81

Reconstituted suspensions contain 125 or 250 mg of cefprozil/5 mL.81

Shake oral suspension well prior to administration of each dose.81

Dosage

Available as cefprozil monohydrate; dosage expressed as anhydrous cefprozil.80 81

Pediatric Patients

General Pediatric Dosage
Oral

Children beyond neonatal period: AAP recommends 15–30 mg/kg daily in 2 equally divided doses for treatment of mild or moderate infections.100 AAP states the drug is inappropriate for treatment of severe infections.100

Acute Otitis Media (AOM)
Oral

Children 6 months to 12 years of age: 15 mg/kg every 12 hours for 10 days.80 81

Pharyngitis and Tonsillitis
Oral

Children 2–12 years of age: 7.5 mg/kg every 12 hours for 10 days.80 81

Children ≥13 years of age: 500 mg once daily for 10 days.80 81

Respiratory Tract Infections
Acute Sinusitis
Oral

Children 6 months to 12 years of age: 7.5 mg/kg every 12 hours for 10 days.80 81 For moderate to severe infections, 15 mg/kg every 12 hours for 10 days.80 81

Children ≥13 years of age: 250 mg every 12 hours for 10 days.80 81 For moderate to severe infections, 500 mg every 12 hours for 10 days.80 81

Secondary Bacterial Infections of Acute Bronchitis
Oral

Children ≥13 years of age: 500 mg every 12 hours for 10 days.80 81

Acute Exacerbations of Chronic Bronchitis
Oral

Children ≥13 years of age: 500 mg every 12 hours for 10 days.80 81

Skin and Skin Structure Infections
Oral

Children 2–12 years of age: 20 mg/kg once every 24 hours for 10 days.80 81

Children ≥13 years of age: 250 or 500 mg every 12 hours for 10 days or 500 mg once daily for 10 days.80 81

Adults

Pharyngitis and Tonsillitis
Oral

500 mg once daily for 10 days.80 81

Respiratory Tract Infections
Acute Sinusitis
Oral

250 mg every 12 hours for 10 days.80 81 For moderate to severe infections, 500 mg every 12 hours for 10 days.80 81

Secondary Bacterial Infections of Acute Bronchitis
Oral

500 mg every 12 hours for 10 days.80 81

Acute Exacerbations of Chronic Bronchitis
Oral

500 mg every 12 hours for 10 days.80 81

Skin and Skin Structure Infections
Oral

250 or 500 mg every 12 hours for 10 days or 500 mg once daily for 10 days.80 81

Special Populations

Hepatic Impairment

Dosage adjustments not required.80 81

Renal Impairment

Dosage adjustments not required in patients with Clcr ≥30 mL/minute.7 80 81

Patients with Clcr <30 mL/minute: Administer 50% of the usual dose using usual dosing intervals.80 81

Hemodialysis patients: Administer cefprozil doses after dialysis sessions.80 81

Geriatric Patients

No dosage adjustments required except those related to renal impairment.80 81 Cautious dosage selection because of age-related decreases in renal function.80 81 See Renal Impairment under Dosage and Administration.

Detailed Cefprozil dosage information

Cautions for Cefprozil

Contraindications

Warnings/Precautions

Warnings

Superinfection/Clostridium difficile-associated Diarrhea and Colitis

Possible emergence and overgrowth of nonsusceptible bacteria or fungi with prolonged use.80 81 Careful observation of the patient is essential.80 81 Institute appropriate therapy if superinfection occurs.80 81

Treatment with anti-infectives alters normal colon flora and may permit overgrowth of Clostridium difficile.80 81 142 C. difficile infection (CDI) and C. difficile-associated diarrhea and colitis (CDAD; also known as antibiotic-associated diarrhea and colitis or pseudomembranous colitis) reported with nearly all anti-infectives, including cefprozil, and may range in severity from mild diarrhea to fatal colitis.80 81 142 C. difficile produces toxins A and B which contribute to development of CDAD;142 hypertoxin-producing strains of C. difficile are associated with increased morbidity and mortality since they may be refractory to anti-infectives and colectomy may be required.80 81

Consider CDAD if diarrhea develops during or after therapy and manage accordingly.80 81 142 Obtain careful medical history since CDAD has been reported to occur as late as 2 months or longer after anti-infective therapy is discontinued.80 81 142

If CDAD is suspected or confirmed, discontinue anti-infectives not directed against C. difficile whenever possible.142 Initiate appropriate supportive therapy (e.g., fluid and electrolyte management, protein supplementation), anti-infective therapy directed against C. difficile (e.g., metronidazole, vancomycin), and surgical evaluation as clinically indicated.71 72 80 81 142

Sensitivity Reactions

Hypersensitivity Reactions

Hypersensitivity reactions (anaphylaxis,80 81 serum-sickness-like reactions,14 80 81 erythema,9 12 Stevens-Johnson syndrome14 80 81 ) have been reported.

If a hypersensitivity reaction occurs, discontinue cefprozil immediately and institute appropriate therapy as indicated (e.g., epinephrine, corticosteroids, and maintenance of an adequate airway and oxygen).80 81

Cross-hypersensitivity

Partial cross-sensitivity among cephalosporins and other β-lactam antibiotics, including penicillins and cephamycins.46 80 81

Prior to initiation of therapy, make careful inquiry concerning previous hypersensitivity reactions to cephalosporins, penicillins, or other drugs.80 81 Cautious use recommended in patients with a history of hypersensitivity to penicillins:80 81 avoid use in those who have had an immediate-type (anaphylactic) hypersensitivity reaction a and administer with caution in those who have had a delayed-type (e.g., rash, fever, eosinophilia) reaction.a

General Precautions

Selection and Use of Anti-infectives

To reduce development of drug-resistant bacteria and maintain effectiveness of cefprozil and other antibacterials, use only for treatment or prevention of infections proven or strongly suspected to be caused by susceptible bacteria.80 81

When selecting or modifying anti-infective therapy, use results of culture and in vitro susceptibility testing.80 81 In the absence of such data, consider local epidemiology and susceptibility patterns when selecting anti-infectives for empiric therapy.80 81

Phenylketonuria

Depending on the manufacturer, oral suspensions containing 125 or 250 mg of cefprozil/5 mL contain aspartame (NutraSweet), which is metabolized in the GI tract to provide 28 mg of phenylalanine per 5 mL.3 81 101 102 103 104 105

History of GI Disease

Cephalosporins should be used with caution in patients with a history of GI disease, particularly colitis.80 81 (See Superinfection/Clostridium difficile-associated Diarrhea and Colitis under Cautions.)

Specific Populations

Pregnancy

Category B.80 81

Lactation

Distributed into milk; use with caution.80 81

Pediatric Use

Safety and efficacy not established in infants <6 months of age for treatment of AOM or acute sinusitis.80 81

Safety and efficacy not established in children <2 years of age for treatment of pharyngitis or tonsillitis or for uncomplicated skin and skin structure infections.80 81

Geriatric Use

Safety and efficacy in those ≥65 years of age similar to that in younger adults, but possibility exists of greater sensitivity to the drug in some geriatric patients.80 81

Substantially eliminated by kidneys; risk of toxicity may be greater in patients with impaired renal function.80 81 Select dosage with caution and consider renal function monitoring since geriatric patients are more likely to have renal impairment.80 81

Hepatic Impairment

Half-life only slightly prolonged.80 81 Dosage adjustments not required.80 81

Renal Impairment

Decreased clearance.80 81

Use with caution in those with known or suspected renal impairment.80 81 Monitor closely and assess renal function prior to and during therapy.80 81

Reduce dosage in those with Clcr <30 mL/minute.80 81 See Renal Impairment under Dosage and Administration.

Common Adverse Effects

Diarrhea, nausea, vomiting, abdominal pain, rash, genital pruritus or vaginitis, dizziness.9 80 81

Drug Interactions

Specific Drugs and Laboratory Tests

Drug or Test

Interaction

Comments

Aminoglycosides

Nephrotoxicity has been reported when aminoglycosides used concomitantly with some cephalosporins80 81

Antacids

Study using capsules (not commercially available) indicate bioavailability not affected when given 5 minutes after an antacid80 81

Diuretics

Caution if used concomitantly with potent diuretics since such drugs may adversely affect renal function80 81

Probenecid

Increased cefprozil AUC80 81

Tests for glucose

Possible false-positive reactions in urine glucose tests using Clinitest, Benedict’s solution, or Fehling’s solution80 81

False-negative reaction possible in blood glucose tests using ferricyanide80 81

Use glucose tests based on enzymatic glucose oxidase reactions (e.g., Clinistix, Tes-Tape)80 81
Cefprozil drug interactions (more detail)

Cefprozil Pharmacokinetics

Absorption

Bioavailability

Bioavailability is 90–95% in fasting adults;21 24 80 81 peak plasma concentrations attained within 1.5 hours.61 80 81

Tablets and oral suspension are bioequivalent under fasting conditions.80 81

Food

Food does not affect absorption or peak plasma concentrations, but time to peak plasma concentrations may be prolonged by 15–45 minutes.80 81

Distribution

Extent

Distributed into various body tissues and fluids including blister fluid,21 22 middle ear fluid,26 and tonsillar and adenoidal tissue.21 27

Distributed into milk in low concentrations.5 80 81

Plasma Protein Binding

35–45%.23 80 81

Elimination

Metabolism

Not appreciably metabolized.21 22 23 24 28

Elimination Route

Eliminated principally in urine by glomerular filtration and tubular secretion.21 22 23 24 28

54–70% of a single dose eliminated unchanged in urine within 24 hours.21 22 23 24 28

Half-life

Adults with normal renal function: 1–1.4 hours.21 22 23 28 80 81

Children 6 months to 12 years of age: 0.94–2.1 hours.13 21 80 81

Special Populations

In geriatric patients, clearance decreased and AUC increased.80 81

Plasma half-life increased slightly in patients with hepatic impairment (about 2 hours).21 80 81

Prolonged plasma half-life (up to 5.2–5.9 hours) in patients with renal impairment.7 80 81

Stability

Storage

Oral

Tablets

20–25°C in tight, light-resistant container.80

For Suspension

20–25°C.81 After reconstitution, store in a refrigerator; discard after 14 days.81

Actions and Spectrum

Advice to Patients

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Cefprozil

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

For suspension

125 mg (of anhydrous cefprozil) per 5 mL*

Cefprozil for Suspension

250 mg (of anhydrous cefprozil) per 5 mL*

Cefprozil for Suspension

Tablets, film-coated

250 mg (of anhydrous cefprozil)*

Cefprozil Film-coated Tablets

500 mg (of anhydrous cefprozil)*

Cefprozil Film-coated Tablets

AHFS DI Essentials™. © Copyright 2024, Selected Revisions October 9, 2013. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

2. Bristol-Myers Squibb US Pharmaceutical Division, Princeton, NJ: Personal communication.

3. Anon. Cefprozil. Med Lett Drugs Ther. 1992; 34:63-4. http://www.ncbi.nlm.nih.gov/pubmed/1608347?dopt=AbstractPlus

4. Arguedas AG, Zaleska M, Stutman HR et al. Comparative trial of cefprozil vs. amoxicillin clavulanate potassium in the treatment of children with acute otitis media with effusion. Pediatr Infect Dis J. 1991; 10:375-80. http://www.ncbi.nlm.nih.gov/pubmed/1906160?dopt=AbstractPlus

5. Shyu WC, Shah VR, Campbell DA et al. Excretion of cefprozil into human breast milk. Antimicrob Agents Chemother. 1992; 36:938-41. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=188771&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/1510416?dopt=AbstractPlus

6. Barriere SL. Pharmacology and pharmacokinetics of cefprozil. Clin Infect Dis. 1992; 14(Suppl 2):S184-8. http://www.ncbi.nlm.nih.gov/pubmed/1617036?dopt=AbstractPlus

7. Shyu WC, Pittman KA, Wilber RB et al. Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment. J Clin Pharmacol. 1991; 31:362-71. http://www.ncbi.nlm.nih.gov/pubmed/2037710?dopt=AbstractPlus

8. Christenson JC, Swenson E, Gooch WM III et al. Comparative efficacy and safety of cefprozil (BMY-28100) and cefaclor in the treatment of acute group A beta-hemolytic streptococcal pharyngitis. Antimicrob Agents Chemother. 1991; 35:1127-30. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=284298&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/1929253?dopt=AbstractPlus

9. Wilber RB, Doyle CA, Durham SJ et al. Safety profile of cefprozil. Clin Infect Dis. 1992; 14(Suppl 2):S264-71. http://www.ncbi.nlm.nih.gov/pubmed/1617047?dopt=AbstractPlus

10. Parish LC, Doyle CA, Durham SJ et al. Cefprozil versus cefaclor in the treatment of mild to moderate skin and skin-structure infections. Clin Ther. 1992; 14:458-69. http://www.ncbi.nlm.nih.gov/pubmed/1638587?dopt=AbstractPlus

11. Christenson JC, Gooch WM, Herrod JN et al. Comparative efficacy and safety of cefprozil and cefaclor in the treatment of acute uncomplicated urinary tract infections. J Antimicrob Chemother. 1991; 28:581-6. http://www.ncbi.nlm.nih.gov/pubmed/1761453?dopt=AbstractPlus

12. Gehanno P, Berche P, Boucot I et al. Comparative efficacy and safety of cefprozil and amoxycillin/clavulanate in the treatment of acute otitis media in children. J Antimicrob Chemother. 1994; 33:1209-18. http://www.ncbi.nlm.nih.gov/pubmed/7928814?dopt=AbstractPlus

13. Saez-Llorens X, Shyu WC, Shelton S et al. Pharmacokinetics of cefprozil in infants and children. Antimicrob Agents Chemother. 1990; 34:2152-5. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=172016&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/2073105?dopt=AbstractPlus

14. Lowery N, Kearns GL, Young RA et al. Serum sickness-like reactions associated with cefprozil therapy. J Pediatr. 1994; 125:325-8. http://www.ncbi.nlm.nih.gov/pubmed/8040786?dopt=AbstractPlus

15. Milatovic D, Adam D, Hamilton H et al. Cefprozil versus penicillin V in treatment of streptococcal tonsillopharyngitis. Antimicrob Agents Chemother. 1993; 37:1620-3. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=188030&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/8215273?dopt=AbstractPlus

16. Bonnet JP, Ginsberg D, Nolen TM et al. Cefprozil vs. cefuroxime axetil in mild to moderate lower respiratory tract infections: a focus on bronchitis. Infect Med. 1992; (Suppl E):1-9.

17. SmithKline & French. Ancef (cefazolin sodium) prescribing information. Philadelphia, PA; 2001 Oct.

19. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: Twenty-first informational supplement. CLSI document M100-S21. Wayne, PA; 2011.

20. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007; 44 Suppl 2:S27-72. http://www.ncbi.nlm.nih.gov/pubmed/17278083?dopt=AbstractPlus

21. Wiseman LR, Benfield P. Cefprozil: a review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential. Drugs. 1993; 45:295-317. http://www.ncbi.nlm.nih.gov/pubmed/7681376?dopt=AbstractPlus

22. Barbhaiya RH, Shukla UA, Gleason CR et al. Phase I study of multiple-dose cefprozil and comparison with cefaclor. Antimicrob Agents Chemother. 1990; 34:1198-1203. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=171784&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/2393281?dopt=AbstractPlus

23. Barbhaiya RH, Shukla WA, Gleason CR et al. Comparison of cefprozil and cefaclor pharmacokinetics and tissue penetration. Antimicrob Agents Chemother. 1990; 34:1204-9. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=171785&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/2393282?dopt=AbstractPlus

24. Shyu WC, Shah VR, Campbell DA et al. Oral absolute bioavailability and intravenous dose-proportionality of cefprozil in humans. J Clin Pharmacol. 1992; 32:798-803. http://www.ncbi.nlm.nih.gov/pubmed/1430299?dopt=AbstractPlus

25. Shyu WC, Wilber RB, Pittman KA et al. Effect of antacid on the bioavailability of cefprozil. Antimicrob Agents Chemother. 1992; 36:962-5. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=188789&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/1510420?dopt=AbstractPlus

26. Shyu WC, Haddad J, Reilly J et al. Penetration of cefprozil in middle ear fluid of patients with otitis media. Antimicrob Agents Chemother. 1994; 38:2210-1. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=284715&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/7811050?dopt=AbstractPlus

27. Shyu WC, Reilly J, Campbell DA et al. Penetration of cefprozil into tonsillar and adenoidal tissues. Antimicrob Agents Chemother. 1993; 37:1180-3. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=187928&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/8517711?dopt=AbstractPlus

28. Lode H, Muller C, Borner K et al. Multiple-dose pharmacokinetics of cefprozil and its impact on intestinal flora of volunteers. Antimicrob Agents Chemother. 1992; 36:144-9. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=189242&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/1590680?dopt=AbstractPlus

29. Thornsberry C. Review of the in vitro antibacterial activity of cefprozil, a new oral cephalosporin. Clin Infect Dis. 1992; 14(Suppl 2):S189-94. http://www.ncbi.nlm.nih.gov/pubmed/1617037?dopt=AbstractPlus

30. Stutman HR, Arguedas AG. Comparison of cefprozil and other antibiotic regimens in the treatment of acute otitis media. Clin Infect Dis. 1992; 14(Suppl 2):S204-8. http://www.ncbi.nlm.nih.gov/pubmed/1617039?dopt=AbstractPlus

32. Brook I, Foote PA. Effect of penicillin or cefprozil therapy on tonsillar flora. J Antimicrob Chemother. 1997; 40:725-8. http://www.ncbi.nlm.nih.gov/pubmed/9421324?dopt=AbstractPlus

33. McCarty JM, Renteria A. Treatment of pharyngitis and tonsillitis with cefprozil: review of three multicenter trials. Clin Infect Dis. 1992; 14(Suppl 2):S224-30. http://www.ncbi.nlm.nih.gov/pubmed/1617042?dopt=AbstractPlus

34. van den Wijngaart W, Verbrugh H, Theopold HM et al. A noncomparative study of cefprozil at two dose levels in the treatment of acute uncomplicated bacterial sinusitis. Clin Ther. 1992; 14:306-13. http://www.ncbi.nlm.nih.gov/pubmed/1611651?dopt=AbstractPlus

35. Nolen TM. Clinical trials of cefprozil for treatment of skin and skin-structure infections: review. Clin Infect Dis. 1992; 14(Suppl 2):S255-63. http://www.ncbi.nlm.nih.gov/pubmed/1617046?dopt=AbstractPlus

36. Blumer JL, Forti WP, Summerhouse TL. Comparison of the efficacy and tolerability of once-daily ceftibuten and twice-daily cefprozil in the treatment of children with acute otitis media. Clin Ther. 1996; 18:811-20. http://www.ncbi.nlm.nih.gov/pubmed/8930425?dopt=AbstractPlus

37. Kafetzis DA. Multi-investigator evaluation of the efficacy and safety of cefprozil, amoxicillin-clavulanate, cefixime and cefaclor in the treatment of acute otitis media. Eur J Clin Microbiol Infect Dis. 1994; 13:857-65. http://www.ncbi.nlm.nih.gov/pubmed/7889960?dopt=AbstractPlus

38. Ball P. Efficacy and safety of cefprozil versus other beta-lactam antibiotics in the treatment of lower respiratory tract infections. Eur J Clin Microbiol Infect Dis. 1994; 13:851-6. http://www.ncbi.nlm.nih.gov/pubmed/7889959?dopt=AbstractPlus

39. McCarty JM. Comparative efficacy and safety of cefprozil versus penicillin, cefaclor and erythromycin in the treatment of streptococcal pharyngitis and tonsillitis. Eur J Clin Microbiol Infect Dis. 1994; 13:846-50. http://www.ncbi.nlm.nih.gov/pubmed/7889958?dopt=AbstractPlus

40. Wise R. Comparative microbiological activity and pharmacokinetics of cefprozil. Eur J Clin Microbiol Infect Dis. 1994; 13:839-45. http://www.ncbi.nlm.nih.gov/pubmed/7889957?dopt=AbstractPlus

41. Shyu WC, Shah VR, Campbell DA et al. Oral absolute bioavailability and intravenous dose-proportionality of cefprozil in humans. J Clin Pharmacol. 1992; 32:798-803. http://www.ncbi.nlm.nih.gov/pubmed/1430299?dopt=AbstractPlus

42. Standaert BB, Finney K, Taylor MT et al. Comparison between cefprozil and penicillin to eradicate pharyngeal colonization of group A beta-hemolytic streptococci. Pediatr Infect Dis J. 1998; 17:39-43. http://www.ncbi.nlm.nih.gov/pubmed/9469393?dopt=AbstractPlus

43. Pichichero ME, McLinn S, Aronovitz G et al. Cefprozil treatment of persistent and recurrent acute otitis media. Pediatr Infect Dis J. 1997; 16:471-8. http://www.ncbi.nlm.nih.gov/pubmed/9154539?dopt=AbstractPlus

44. Kozyrskyj AL, Hildes-Ripstein GE, Longstaffe SEA et al. Treatment of acute otitis media with a shortened course of antibiotics: a meta-analysis. JAMA. 1998; 279:1736-42. http://www.ncbi.nlm.nih.gov/pubmed/9624028?dopt=AbstractPlus

45. Kafetzis DA, Astra H, Mitropoulos L. Five-day versus ten-day treatment of acute otitis media with cefprozil. Eur J Clin Microbiol Infect Dis. 1997; 16:283-6. http://www.ncbi.nlm.nih.gov/pubmed/9177961?dopt=AbstractPlus

46. Kishiyam JL, Adelman DC. The cross-reactivity and immunology of β-lactam antibiotics. Drug Safety. 1994; 10:318-27. http://www.ncbi.nlm.nih.gov/pubmed/8018304?dopt=AbstractPlus

47. Thompson JW, Jacobs RF. Adverse effects of newer cephalosporins: an update. Drug Safety. 1993; 9:132-42. http://www.ncbi.nlm.nih.gov/pubmed/8397890?dopt=AbstractPlus

49. Anon. Drugs for bacterial infections. Med Lett Treat Guid. 2010; 8:43-52.

52. Pichichero ME, Cohen R. Shortened course of antibiotic therapy for acute otitis media, sinusitis and tonsillopharyngitis. Pediatr Infect Dis J. 1997; 16:680-95. http://www.ncbi.nlm.nih.gov/pubmed/9239773?dopt=AbstractPlus

53. Tack KJ, Henry DC, Gooch WM et al et al. Five-day cefdinir treatment for streptococcal pharyngitis. Antimicrob Agents Chemother. 1998; 42:1073-5. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=105747&blobtype=pdf http://www.ncbi.nlm.nih.gov/pubmed/9593129?dopt=AbstractPlus

54. Pichichero ME. Cephalosporins are superior to penicillin for treatment of streptococcal tonsillopharyngitis: is the difference worth it? Pediatr Infect Dis. 1993; 12:268-74.

55. Dajani AS, Kessler SL, Mendelson R et al. Cefpodoxime proxetil vs. penicillin V in pediatric streptococcal pharyngitis/tonsillitis. Pediatr Infect Dis J. 1993; 12:275-9. http://www.ncbi.nlm.nih.gov/pubmed/8483620?dopt=AbstractPlus

56. Aujard Y, Boucot I, Brahimi N et al. Comparative efficacy and safety of four-day cefuroxime axetil and ten-day penicillin treatment of group A beta-hemolytic streptococcal pharyngitis in children. Pediatr Infect Dis J. 1995; 14:295-300. http://www.ncbi.nlm.nih.gov/pubmed/7603811?dopt=AbstractPlus

57. Mehra S, Van Moerkerke M, Welck J et al. Short course therapy with cefuroxime axetil for group A streptococcal tonsillopharyngitis in children. Pediatr Infect Dis J. 1998; 17:452-7. http://www.ncbi.nlm.nih.gov/pubmed/9655533?dopt=AbstractPlus

58. Milatovic D. Evaluation of cefadroxil, penicillin and erythromycin in the treatment of streptococcal tonsillopharyngitis. Pediatr Infect Dis J. 1991; 10:S61-3. http://www.ncbi.nlm.nih.gov/pubmed/1945599?dopt=AbstractPlus

60. Reviewers’ comments (personal observations).

61. Bristol-Myers Squibb, Plainsboro, NJ. Personal communication.

62. Aronovitz G. Treatment of upper and lower respiratory tract infections: clinical trials with cefprozil. J Pediatr Infect Dis J. 1998; 17:S83-8.

63. Nolen T, Conetta BJ, Durham SJ et al. Safety and efficacy of cefprozil vs. cefaclor in the treatment of mild to moderate skin and skin structure infections. Infect Med. 1992; 9(Supp C):56-68.

64. McCarty JM, Renteria A, Doyle CA et al. Cefprozil v. cefaclor in the treatment of pharyngitis and tonsillitis. Infect Med. 1992; 9(Suppl C):33-43.

65. Russell MD, Nolen T, Allen JM et al. Cefprozil versus amoxicillin/clavulanate in the treatment of acute, uncomplicated maxillary sinusitis in adults; a randomized, prospective clinical trial. Infect Med. 1997; 14(Suppl A):43-50.

66. Gwaltney JM. Acute community-acquired sinusitis. Clin Infect Dis. 1996; 23:1209-25. http://www.ncbi.nlm.nih.gov/pubmed/8953061?dopt=AbstractPlus

67. Evans KL. Recognition and management of sinusitis. Drugs. 1998; 56:59-71. http://www.ncbi.nlm.nih.gov/pubmed/9664199?dopt=AbstractPlus

68. Gwaltney JM. Sinusitis. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett’s principles and practices of infectious diseases. 4th ed. New York: Churchill Livingston; 1995: 585-90.

71. Fekety R for the American College of Gastroenterology Practice Parameters Committee. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol. 1997; 92:739-50. http://www.ncbi.nlm.nih.gov/pubmed/9149180?dopt=AbstractPlus

72. American Society of Health-System Pharmacists Commission on Therapeutics. ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease. Am J Health-Syst Pharm. 1998; 55:1407-11. http://www.ncbi.nlm.nih.gov/pubmed/9659970?dopt=AbstractPlus

74. Dowell SF, Marcy SM, Phillips WR et al. Otitis media—principles of judicious use of antimicrobial agents. Pediatrics. 1998; 101:165-71.

75. Paradise JL. Managing otitis media: a time for change. Pediatrics. 1995; 96:712-5. http://www.ncbi.nlm.nih.gov/pubmed/7567336?dopt=AbstractPlus

77. Heffelfinger JD, Dowell SF, Jorgensen JH et al. Management of community-acquired pneumonia in the era of pneumococcal resistance. A report from the drug-resistant Streptococcus pneumoniae therapeutic working group. Arch Intern Med. 2000; 160:1399-1408. http://www.ncbi.nlm.nih.gov/pubmed/10826451?dopt=AbstractPlus

80. Lupin Pharmaceuticals Inc. Cefprozil tablets prescribing information. Baltimore, MD; 2007 Dec.

81. Lupin Pharmaceuticals Inc. Cefprozil powder for oral suspension USP 125 mg/5 mL and 250 mg/5 mL prescribing information. Baltimore, MD; 2007 Dec.

100. American Academy of Pediatrics. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.

101. American Medical Association Council on Scientific Affairs. Aspartame: review of safety issues. JAMA. 1985; 254:400 2. http://www.ncbi.nlm.nih.gov/pubmed/2861297?dopt=AbstractPlus

102. Gossel TA. A review of aspartame: characteristics, safety and uses. US Pharm. 1984; 9:26,28 30.

103. Food and Drug Administration. Aspartame as an inactive ingredient in human drug products; labeling requirements. Proposed rule. [21 CFR Part 201] Fed Regist. 1983; 48:54993 5.

104. Food and Drug Administration. Food additives permitted for direct addition to food for human consumption; aspartame. Final rule. [21 CFR Part 172] Fed Regist. 1983; 48:31376 82.

105. Anon. Aspartame and other sweeteners. Med Lett Drugs Ther. 1982; 24:1 2.

116. Shulman ST, Bisno AL, Clegg HW et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis. 2012; 55:1279-82. http://www.ncbi.nlm.nih.gov/pubmed/23091044?dopt=AbstractPlus

117. Gerber MA, Baltimore RS, Eaton CB et al. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. 2009; 119:1541-51. http://www.ncbi.nlm.nih.gov/pubmed/19246689?dopt=AbstractPlus

142. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010; 31:431-55. http://www.ncbi.nlm.nih.gov/pubmed/20307191?dopt=AbstractPlus

143. Chow AW, Benninger MS, Brook I et al. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012; 54:e72-e112. http://www.ncbi.nlm.nih.gov/pubmed/22438350?dopt=AbstractPlus

144. Wald ER, Applegate KE, Bordley C et al. Clinical Practice Guideline for the Diagnosis and Management of Acute Bacterial Sinusitis in Children Aged 1 to 18 Years. Pediatrics. 2013; :. http://www.ncbi.nlm.nih.gov/pubmed/23796742?dopt=AbstractPlus

165. Lieberthal AS, Carroll AE, Chonmaitree T et al. The diagnosis and management of acute otitis media. Pediatrics. 2013; 131:e964-99. http://www.ncbi.nlm.nih.gov/pubmed/23439909?dopt=AbstractPlus

a. AHFS drug information 2003. McEvoy GK, ed. Cephalosporins General Statement. Bethesda, MD: American Society of Health-System Pharmacists; 2003: 125-39.

Medical Disclaimer